These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 25669662)

  • 21. A multicenter phase II study of erlotinib and sorafenib in chemotherapy-naive patients with advanced non-small cell lung cancer.
    Lind JS; Dingemans AM; Groen HJ; Thunnissen FB; Bekers O; Heideman DA; Honeywell RJ; Giovannetti E; Peters GJ; Postmus PE; van Suylen RJ; Smit EF
    Clin Cancer Res; 2010 Jun; 16(11):3078-87. PubMed ID: 20395213
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Phase I study of the HER3-targeted antibody patritumab (U3-1287) combined with erlotinib in Japanese patients with non-small cell lung cancer.
    Nishio M; Horiike A; Murakami H; Yamamoto N; Kaneda H; Nakagawa K; Horinouchi H; Nagashima M; Sekiguchi M; Tamura T
    Lung Cancer; 2015 Jun; 88(3):275-81. PubMed ID: 25891541
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A phase Ib, dose-finding study of erlotinib in combination with a fixed dose of pertuzumab in patients with advanced non-small-cell lung cancer.
    Felip E; Ranson M; Cedrés S; Dean E; Brewster M; Martínez P; McNally V; Ross G; Galdermans D
    Clin Lung Cancer; 2012 Nov; 13(6):432-41. PubMed ID: 22609229
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A phase I, pharmacokinetic, and pharmacodynamic study of panobinostat, an HDAC inhibitor, combined with erlotinib in patients with advanced aerodigestive tract tumors.
    Gray JE; Haura E; Chiappori A; Tanvetyanon T; Williams CC; Pinder-Schenck M; Kish JA; Kreahling J; Lush R; Neuger A; Tetteh L; Akar A; Zhao X; Schell MJ; Bepler G; Altiok S
    Clin Cancer Res; 2014 Mar; 20(6):1644-55. PubMed ID: 24429877
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Phase I dose-escalation study of the PI3K/mTOR inhibitor voxtalisib (SAR245409, XL765) plus temozolomide with or without radiotherapy in patients with high-grade glioma.
    Wen PY; Omuro A; Ahluwalia MS; Fathallah-Shaykh HM; Mohile N; Lager JJ; Laird AD; Tang J; Jiang J; Egile C; Cloughesy TF
    Neuro Oncol; 2015 Sep; 17(9):1275-83. PubMed ID: 26019185
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Phase I dose-escalation study of oral vinflunine in combination with erlotinib in pre-treated and unselected EGFR patients with locally advanced or metastatic non-small-cell lung cancer.
    Krzakowski M; Bennouna J; Dansin E; Kowalski D; Hiret S; Penel N; Favrel S; Tourani JM
    Cancer Chemother Pharmacol; 2014 Feb; 73(2):231-6. PubMed ID: 24220936
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Antitumor activity and safety of combination therapy with the Toll-like receptor 9 agonist IMO-2055, erlotinib, and bevacizumab in advanced or metastatic non-small cell lung cancer patients who have progressed following chemotherapy.
    Smith DA; Conkling P; Richards DA; Nemunaitis JJ; Boyd TE; Mita AC; de La Bourdonnaye G; Wages D; Bexon AS
    Cancer Immunol Immunother; 2014 Aug; 63(8):787-96. PubMed ID: 24770667
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Erlotinib and vinorelbine in advanced malignant solid tumors: a phase I study.
    Davies AM; Ho C; Hesketh PJ; Beckett LA; Lara PN; Lau DH; Gandara DR
    Invest New Drugs; 2007 Aug; 25(4):351-5. PubMed ID: 17440682
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lung cancer.
    Herbst RS; Johnson DH; Mininberg E; Carbone DP; Henderson T; Kim ES; Blumenschein G; Lee JJ; Liu DD; Truong MT; Hong WK; Tran H; Tsao A; Xie D; Ramies DA; Mass R; Seshagiri S; Eberhard DA; Kelley SK; Sandler A
    J Clin Oncol; 2005 Apr; 23(11):2544-55. PubMed ID: 15753462
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Phase I and pharmacokinetic study of erlotinib administered in combination with amrubicin in patients with previously treated, advanced non-small cell lung cancer.
    Otani S; Hamada A; Sasaki J; Wada M; Yamamoto M; Ryuge S; Takakura A; Fukui T; Yokoba M; Mitsufuji H; Toyooka I; Maki S; Kimura M; Hayashi N; Ishihara M; Kasajima M; Hiyoshi Y; Katono K; Asakuma M; Igawa S; Kubota M; Katagiri M; Saito H; Masuda N
    Am J Clin Oncol; 2015 Aug; 38(4):405-10. PubMed ID: 26214085
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Phase I-IIa study of BMS-690514, an EGFR, HER-2 and -4 and VEGFR-1 to -3 oral tyrosine kinase inhibitor, in patients with advanced or metastatic solid tumours.
    Soria JC; Baselga J; Hanna N; Laurie SA; Bahleda R; Felip E; Calvo E; Armand JP; Shepherd FA; Harbison CT; Berman D; Park JS; Zhang S; Vakkalagadda B; Kurland JF; Pathak AK; Herbst RS
    Eur J Cancer; 2013 May; 49(8):1815-24. PubMed ID: 23490650
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A phase I dose-escalation study of Selumetinib in combination with Erlotinib or Temsirolimus in patients with advanced solid tumors.
    Infante JR; Cohen RB; Kim KB; Burris HA; Curt G; Emeribe U; Clemett D; Tomkinson HK; LoRusso PM
    Invest New Drugs; 2017 Oct; 35(5):576-588. PubMed ID: 28424891
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Sunitinib plus erlotinib for the treatment of advanced/metastatic non-small-cell lung cancer: a lead-in study.
    Blumenschein GR; Ciuleanu T; Robert F; Groen HJ; Usari T; Ruiz-Garcia A; Tye L; Chao RC; Juhasz E
    J Thorac Oncol; 2012 Sep; 7(9):1406-16. PubMed ID: 22743295
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Phase I dose-finding and pharmacokinetic study of the oral epidermal growth factor receptor tyrosine kinase inhibitor Ro50-8231 (erlotinib) in Japanese patients with solid tumors.
    Yamamoto N; Horiike A; Fujisaka Y; Murakami H; Shimoyama T; Yamada Y; Tamura T
    Cancer Chemother Pharmacol; 2008 Mar; 61(3):489-96. PubMed ID: 17483950
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Phase I/II trial of vorinostat (SAHA) and erlotinib for non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutations after erlotinib progression.
    Reguart N; Rosell R; Cardenal F; Cardona AF; Isla D; Palmero R; Moran T; Rolfo C; Pallarès MC; Insa A; Carcereny E; Majem M; De Castro J; Queralt C; Molina MA; Taron M
    Lung Cancer; 2014 May; 84(2):161-7. PubMed ID: 24636848
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Phase Ib trial of the oral angiogenesis inhibitor pazopanib administered concurrently with erlotinib.
    Dy GK; Infante JR; Eckhardt SG; Novello S; Ma WW; Jones SF; Huff A; Wang Q; Suttle AB; Ottesen LH; Adjei AA; Burris HA
    Invest New Drugs; 2013 Aug; 31(4):891-9. PubMed ID: 23135778
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A phase 1b trial of the combination of an all-oral regimen of capecitabine and erlotinib in advanced non-small cell lung cancer in Caucasian patients.
    Kumar R; Lu SK; Minchom A; Sharp A; Davidson M; Gunapala R; Yap TA; Bhosle J; Popat S; O'Brien ME
    Cancer Chemother Pharmacol; 2016 Feb; 77(2):375-83. PubMed ID: 26706729
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A phase Ib dose-escalation and expansion study of the oral MEK inhibitor pimasertib and PI3K/MTOR inhibitor voxtalisib in patients with advanced solid tumours.
    Schram AM; Gandhi L; Mita MM; Damstrup L; Campana F; Hidalgo M; Grande E; Hyman DM; Heist RS
    Br J Cancer; 2018 Dec; 119(12):1471-1476. PubMed ID: 30425349
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Phase I/II Study of HSP90 Inhibitor AUY922 and Erlotinib for EGFR-Mutant Lung Cancer With Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors.
    Johnson ML; Yu HA; Hart EM; Weitner BB; Rademaker AW; Patel JD; Kris MG; Riely GJ
    J Clin Oncol; 2015 May; 33(15):1666-73. PubMed ID: 25870087
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Phase I study of cetuximab, erlotinib, and bevacizumab in patients with advanced solid tumors.
    Lin CC; Calvo E; Papadopoulos KP; Patnaik A; Sarantopoulos J; Mita AC; Preston GG; Mita MM; Rodon J; Mays T; Yeh IT; O'Rourke P; Takimoto CH; Dancey JE; Chen H; Tolcher AW
    Cancer Chemother Pharmacol; 2009 May; 63(6):1065-71. PubMed ID: 18795291
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.